RZLT
$2.49+0.02 (+0.81%)
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Recent News
XOMA Royalty Q4 Earnings Call Highlights
XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig
Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing
Rezolute Inc. (NASDAQ:RZLT) is one of the best biotech penny stocks to buy according to analysts. On December 11, Rezolute released topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism/HI. The study, which included 63 participants aged 3 months to 45 years across more than a dozen countries, did […]
Insiders Made Their Bets in 2025—These Were the Top 5 Stocks They Bought
Insiders bought these stocks heavily in 2025, but investors should be wary; only some of them are good buys for 2026 portfolios.
Chief Financial Officer of Rezolute Daron Evans Buys 21% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Rezolute, Inc. ( NASDAQ:RZLT ) Chief Financial...
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.